
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer
AstraZeneca has added another indication to its blockbuster immunotherapy Imfinzi (durvalumab), gaining European approval to treat a type of bladder cancer. Imfinzi is now approved to treat adult patients with resectable muscle-invasive bladder cancer ( …